Viridian Therapeutics (NASDAQ:VRDN) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Viridian Therapeutics (NASDAQ:VRDN) from a strong sell rating to a sell rating in a report published on Saturday morning.

VRDN has been the topic of several other research reports. Evercore reiterated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. Truist Financial cut their price target on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Royal Bank Of Canada boosted their price target on Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright cut their price target on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, May 5th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.31.

Viridian Therapeutics Trading Down 2.3%

NASDAQ:VRDN opened at $16.61 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.65 and a current ratio of 15.15. Viridian Therapeutics has a one year low of $12.07 and a one year high of $34.29. The business’s 50-day simple moving average is $21.57 and its 200 day simple moving average is $26.94. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -5.00 and a beta of 0.82.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.04 million. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. The company’s revenue was up 95.8% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics will post -3.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

Institutional investors have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Viridian Therapeutics in the 4th quarter valued at about $36,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at about $35,000. KBC Group NV acquired a new stake in shares of Viridian Therapeutics in the 1st quarter valued at about $34,000. Farther Finance Advisors LLC raised its stake in shares of Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares in the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after purchasing an additional 1,886 shares in the last quarter.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several future periods, including FY2026, FY2027, FY2028, FY2029 and FY2030, while keeping a Buy rating and a $22 price target, suggesting improving longer-term outlook for Viridian Therapeutics.
• Positive Sentiment: Needham & Company reiterated its Buy rating on Viridian Therapeutics, adding to the recent cluster of bullish analyst support. Viridian Therapeutics’ (VRDN) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Multiple brokerage updates lifted target prices on VRDN, with one report citing an average target of about $37.07, reflecting continued optimism from analysts. Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Target Price at $37.07
• Negative Sentiment: Viridian Therapeutics completed pricing on an upsized concurrent offering of 1.75% convertible senior notes due 2032 and common stock for $350 million, which can dilute existing shareholders and usually weighs on the stock near term. Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings…
• Negative Sentiment: Market articles also highlighted the financing as a key reason for recent volatility, even as investors look ahead to commercialization of its drug pipeline. Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.